Brind.

Immunocore Holdings presented clinical trial data at the ASCO meeting, with stock benefiting from Trump-era tariffs.

1 report, 1 independent Updated Jun 22
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Immunocore Holdings presented clinical trial data at the ASCO meeting, with stock benefiting from Trump-era tariffs.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped